Drug Discovery World
AUGUST 16, 2023
Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. This landscape is rapidly changing.
pharmaphorum
JANUARY 26, 2023
Protein prediction algorithms will reach their potential Proteomics has long been hindered by inaccurate or incomplete RNA sequences – with resultant predictive models built from RNA proving inaccurate. The post A new dawn of the genomic age: five areas set to be transformed in 2023 appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 7, 2022
One might argue that this all started getting exciting with the launch of the Human Genome Project, which the National Human Genome Research Institute consider to be one of the greatest scientific feats in history 1. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact. .
Drug Discovery World
MARCH 13, 2024
Dr Gokhale expands on the country’s leadership role: “Singapore is a great example of integration of genomic medicine in healthcare via population scale research. The SG100K/PRECISE project is exemplar of how multi-dimensional population scale genomics projects when done right, can have a significant impact on the practice of medicine.
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.
Roots Analysis
AUGUST 28, 2022
As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. The trend is unlikely to change in the foreseen future. Concluding Remarks.
Drug Discovery World
OCTOBER 6, 2022
Both the binary and quantitative have relied on measurement of protein, DNA, and more recently, RNA. He is the founder and CEO of Cofactor Genomics, a diagnostic company leveraging the power of RNA and machine learning to build disease models.
Expert insights. Personalized for you.
52 
Let's personalize your content